Zhejiang Hisun Pharmaceutical's Subsidiary Passes GMP Compliance Inspection

Stock News12-03

Zhejiang Hisun Pharmaceutical Co.,Ltd. (600267.SH) announced that its wholly-owned subsidiary, Hisun Pharmaceutical Nantong Co., Ltd., recently received the "Drug GMP Compliance Inspection Notice" (No. Su-Yao-Jian-Yao-Sheng-Gao-Zhi [2025] 438) from the Jiangsu Provincial Drug Administration.

During this GMP compliance inspection, the minocycline hydrochloride active pharmaceutical ingredient (API) underwent its first pre-market GMP compliance check. The corresponding production line also passed its first GMP compliance inspection since being newly established.

As of now, the cumulative investment in fixed assets related to the above-mentioned workshop amounts to approximately 99.16 million yuan, of which about 86.30 million yuan has already been invested (unaudited).

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1169581205?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-03 17:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1169581205","market":"other","top_or_hot":-1,"title":"Zhejiang Hisun Pharmaceutical's Subsidiary Passes GMP Compliance Inspection","media":"Stock News","content":"<p>Zhejiang Hisun Pharmaceutical Co.,Ltd. (600267.SH) announced that its wholly-owned subsidiary, Hisun Pharmaceutical Nantong Co., Ltd., recently received the \"Drug GMP Compliance Inspection Notice\" (No. Su-Yao-Jian-Yao-Sheng-Gao-Zhi [2025] 438) from the Jiangsu Provincial Drug Administration.</p>\n<p>During this GMP compliance inspection, the minocycline hydrochloride active pharmaceutical ingredient (API) underwent its first pre-market GMP compliance check. The corresponding production line also passed its first GMP compliance inspection since being newly established.</p>\n<p>As of now, the cumulative investment in fixed assets related to the above-mentioned workshop amounts to approximately 99.16 million yuan, of which about 86.30 million yuan has already been invested (unaudited).</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Zhejiang Hisun Pharmaceutical's Subsidiary Passes GMP Compliance Inspection</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nZhejiang Hisun Pharmaceutical's Subsidiary Passes GMP Compliance Inspection\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-12-03 17:46</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Zhejiang Hisun Pharmaceutical Co.,Ltd. (600267.SH) announced that its wholly-owned subsidiary, Hisun Pharmaceutical Nantong Co., Ltd., recently received the \"Drug GMP Compliance Inspection Notice\" (No. Su-Yao-Jian-Yao-Sheng-Gao-Zhi [2025] 438) from the Jiangsu Provincial Drug Administration.</p>\n<p>During this GMP compliance inspection, the minocycline hydrochloride active pharmaceutical ingredient (API) underwent its first pre-market GMP compliance check. The corresponding production line also passed its first GMP compliance inspection since being newly established.</p>\n<p>As of now, the cumulative investment in fixed assets related to the above-mentioned workshop amounts to approximately 99.16 million yuan, of which about 86.30 million yuan has already been invested (unaudited).</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0239","symbol_name":"医药制造","start_time":0,"source_url":"","article_id":"1169581205","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1169581205","pubTimestamp":1764755196,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Zhejiang Hisun Pharmaceutical Co.,Ltd. (600267.SH) announced that its wholly-owned subsidiary, Hisun Pharmaceutical Nantong Co., Ltd., recently received the \"Drug GMP Compliance Inspection Notice\"...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"600267":"海正药业","BK0239":"医药制造","BK0028":"国家队","BK0060":"抗癌","BK0188":"融资融券"},"translate_title":"浙江海正药业子公司通过GMP符合性检查","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600267":1},"content_text":"Zhejiang Hisun Pharmaceutical Co.,Ltd. (600267.SH) announced that its wholly-owned subsidiary, Hisun Pharmaceutical Nantong Co., Ltd., recently received the \"Drug GMP Compliance Inspection Notice\" (No. Su-Yao-Jian-Yao-Sheng-Gao-Zhi [2025] 438) from the Jiangsu Provincial Drug Administration.\nDuring this GMP compliance inspection, the minocycline hydrochloride active pharmaceutical ingredient (API) underwent its first pre-market GMP compliance check. The corresponding production line also passed its first GMP compliance inspection since being newly established.\nAs of now, the cumulative investment in fixed assets related to the above-mentioned workshop amounts to approximately 99.16 million yuan, of which about 86.30 million yuan has already been invested (unaudited).","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"policyRegulatory","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1169581205","isCrawlerRequest":true}